Combining the GLP-1 peptide drug semaglutide with canagliflozin improved kidney protein leakage, blood sugar, cholesterol, and insulin resistance more than canagliflozin alone in diabetic kidney disease patients.
ACR p=0.002The albumin-to-creatinine ratio — a key marker of kidney damage — improved significantly more with the semaglutide-canagliflozin combination versus canagliflozin alone
What the researchers found
Adding semaglutide to canagliflozin produced superior outcomes compared to canagliflozin alone in 211 patients with diabetic nephropathy over 6 months. The combination therapy showed significantly better results across multiple measures: albumin-to-creatinine ratio (145.87 vs 158.11 mg/g, p=0.002), HbA1c (7.08% vs 7.42%, p=0.005), LDL cholesterol (86.74 vs 94.86 mg/dL, p=0.032), free fatty acids (0.46 vs 0.52 mmol/L, p=0.002), and insulin resistance index (3.94 vs 4.08, p=0.011).
Pancreatic β-cell function also improved with combination therapy (51.22 vs 49.36, p=0.022), and adverse event rates were comparable between groups with no increase in gastrointestinal side effects.
Why it matters
Diabetic nephropathy is the leading cause of end-stage kidney disease, and both semaglutide (a GLP-1 peptide drug) and canagliflozin (an SGLT2 inhibitor) are individually recommended for treatment. This study provides the first direct comparison of the combination versus monotherapy, showing the peptide drug adds meaningful kidney and metabolic benefits without extra side effects — supporting a dual-therapy approach.
The numbers in context
n=211 (107 mono, 104 combo) · 6-month follow-up · ACR 145.87 vs 158.11 mg/g (p=0.002) · HbA1c 7.08% vs 7.42% (p=0.005) · LDL 86.74 vs 94.86 mg/dL (p=0.032) · No increase in adverse events
How the study worked
Retrospective study using electronic medical records from Henan Provincial People's Hospital (October 2022 – March 2024). Patients with type 2 diabetic nephropathy were divided into canagliflozin monotherapy (n=107) or canagliflozin plus semaglutide combination (n=104). Renal function, glucose metabolism, lipid profiles, pancreatic function, oxidative stress, and inflammatory markers were assessed at baseline and 6 months. Adverse events were monitored throughout.
Who was studied
Adults with type 2 diabetes and diabetic nephropathy treated at a single Chinese hospital from 2022–2024
What this study cannot tell us
This is a retrospective, non-randomized study from a single hospital, introducing potential selection bias — patients prescribed the combination may differ systematically from monotherapy patients. The 6-month follow-up is relatively short for kidney outcomes. Long-term kidney function preservation (eGFR decline, progression to dialysis) was not assessed. The study lacks randomization and blinding, limiting causal conclusions.
How to read the evidence
This is a retrospective observational study from a single center without randomization. While it provides useful real-world data, it is subject to selection bias and confounding. Results need confirmation in randomized controlled trials.
When this study was published
Published in 2026 with data from 2022–2024, this is very recent evidence on a clinically relevant question about combining two of the most important drug classes in diabetes management.
The bigger picture
The combination of GLP-1 peptide agonists and SGLT2 inhibitors is increasingly used in clinical practice, but most evidence comes from trials studying each drug class separately. This study adds to the growing body of evidence supporting dual therapy, specifically for diabetic nephropathy — a condition where preventing kidney deterioration can spare patients from dialysis. If confirmed in randomized trials, this combination could become standard of care for diabetic kidney disease.
Questions still open
- Will randomized controlled trials confirm the additive kidney benefits of semaglutide plus canagliflozin?
- Does the combination therapy slow long-term eGFR decline and delay progression to dialysis?
- Is the semaglutide-canagliflozin combination more effective than other GLP-1/SGLT2 inhibitor pairings?
Common questions
Why combine two diabetes drugs for kidney protection?
What is the albumin-to-creatinine ratio and why does it matter?
Read the original research
Renal and metabolic effects of semaglutide plus canagliflozin vs canagliflozin alone in type 2 diabetic nephropathy.
World journal of diabetes, 17(2), 112867
Citation
Miao, Yan; He, Pan; Wang, Dan-Yu; Yan, Lei; Cao, Hui-Xia; Shao, Feng-Min. (2026). Renal and metabolic effects of semaglutide plus canagliflozin vs canagliflozin alone in type 2 diabetic nephropathy.. World journal of diabetes, 17(2), 112867. https://doi.org/10.4239/wjd.v17.i2.112867